Our goal is to build a broad pipeline of assets as the receptor company of choice for stem cell researchers in Canada and internationally. We intend to build upon the strength of our existing proprietary candidates, NTx®-265, NTx®-428 and NTx®-488, from the work of Dr. Weiss from the Hotchkiss Brain Institute to develop a diverse pipeline that positions us as a leader in stem cell therapeutics. Using a milestone-based approach we intend to raise capital to fund these candidates through identifiable value events that will inform further licensing and/or development decisions.
Our team is actively conducting due diligence on candidates to potentially acquire or in-license as the first step forward in our pipeline expansion.
NTx®-265 has been designed as a novel therapy to rebuild brain matter following a human stroke. The regeneration of new, functional brain matter may directly influence a patient’s prognosis and the degree to which symptoms are minimized We have already met with the U.S. FDA to solicit their input on the design of a pivotal trial. Final design agreement would be pursued should sufficient capital resources be secured to conduct the trial.
SCT is currently conducting a Phase II clinical trial designed to characterize the ability of either hCG or prolactin followed by EPO to promote neurological and functional recovery of the brain following moderate-to-serious acute cortical (white matter) injury to the brain.
SCT has substantial intellectual property relating to the use of regenerative therapies for treating demyelinating diseases such as multiple sclerosis (MS) using the potential therapeutic effects of prolactin on the central nervous system by promoting remyelination of the brain and spinal cord.
Note: Quotes are delayed. For informational purposes only.